Another idea towards developing a LRRK2 targeted therapy could be that, since LRRK2 is a complex protein, it might be difficult to modify its pathogenic activity directly instead we can target the impaired PD pathways associated with LRRK2 by targeting these interactors. The gene discussed is LRRK2; the disease is Parkinson disease.